Tag: EpiPen

When Healthy Policy Neglects Economic Principles, Patients Suffer »

Recent events indicate an urgent need for researchers and policymakers to relearn the basics.

Let Competition, Not the FDA, Resolve the EpiPen Shortage »

The only reliable remedy to mitigate shortages of any product is to allow competition in the market.

EpiPen Pricing Controversy Reveals Ignorance about Market Competition »

Increased competition is the remedy to skyrocketing drug prices.

One Solution to the EpiPen Crisis: Repeal Durham-Humphrey! »

Posturing politicians on Capitol Hill conducted a hearing a few days ago during which they grilled Heather Bresch, CEO of Mylan N.V., maker of EpiPens. Prices of EpiPens have skyrocketed in the past few years (which I have discussed here and here). The politicians were more interested in wagging their fingers and tut-tutting at...
Read More »

EpiPen: A Case Study in Health Insurance Failure »

I recently wrote a post describing EpiPen as a “Case Study in Government Harm,” describing how the government had made it possible for the manufacturer to increase prices of the life-saving drug multiple times without fear of retaliation. It is also a case study in how health insurance distorts our choices and increases their...
Read More »

EpiPen: A Case Study of Government Harm »

Much has been written about the dramatic price hikes for EpiPen, a product that injects a drug that counters severe allergic reactions (anaphylactic shock). According to Aaron E. Carroll, writing in the New York Times, the real (inflation adjusted) price of EpiPens has risen 4.5 times since 2004. Both Carrol and the Wall Street...
Read More »

  • Catalyst
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org